What is the typical dosing frequency and duration of cerebrolysin (neuroprotective peptide) treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cerebrolysin Dosing Frequency

Cerebrolysin is typically administered once daily via intravenous infusion for 10-21 consecutive days, with the most common treatment duration being 21 days.

Standard Dosing Schedule

Acute Ischemic Stroke

  • Cerebrolysin is given as a single daily intravenous infusion of 30-50 mL for 10-21 consecutive days, with treatment initiation within 72 hours after stroke onset 1
  • The typical protocol uses 15-30 mL daily for 21 days in acute middle cerebral artery stroke 2
  • Treatment should begin within 72 hours of symptom onset for optimal efficacy 1

Dementia (Alzheimer's Disease and Vascular Dementia)

  • Cerebrolysin is administered at 30 mL once daily via intravenous infusion, with an average treatment duration of 17.8 days in clinical practice 3
  • Treatment courses typically last 10-28 weeks depending on the severity and type of dementia 4
  • The medication is given as a single daily infusion, not divided into multiple doses throughout the day 3

Dose-Response Relationship

  • Higher doses (≥2.5 mL/kg) demonstrate significantly better neurological recovery compared to lower doses, though differences between effective doses above this threshold are not statistically significant 5
  • Doses of 5.0 mL/kg showed additional benefit in reducing infarct volume beyond functional improvement 5
  • The dose-dependent effect is significant (p < 0.001) for neurological outcomes 5

Treatment Duration Considerations

  • Longer treatment courses (21 days) are preferred over shorter durations (10 days) for acute stroke, as the number needed to treat for clinically relevant changes is 7.7 (95% CI 5.2 to 15.0) 1
  • Timely pharmacological intervention leads to best therapeutic results, with younger, less severely affected patients showing significantly larger improvements (p < 0.05) than older, more seriously ill patients 3
  • The medication demonstrates comparable safety to placebo across all dosing regimens studied 1

Administration Method

  • Cerebrolysin must be given parenterally (intravenously) as it is a peptide preparation that cannot be administered orally 4
  • The medication is administered as an intravenous infusion once daily, not as a bolus injection 2, 3

References

Research

Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2018

Research

[Cerebrolysin in treatment of acute ischemic stroke].

Neurologia i neurochirurgia polska, 1995

Research

Therapeutic results with Cerebrolysin in the treatment of dementia.

Wiener medizinische Wochenschrift (1946), 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.